Resolutions from the Annual General Meeting 2025

03.04.25 17:42 Uhr

Werte in diesem Artikel
Aktien

54,48 EUR -0,38 EUR -0,69%

Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted.

 The following resolutions were made:

Wer­bung

  • Approval of the audited Annual Report for 2024
  • Approval of distribution of profit with payment of an ordinary dividend of DKK 4.20 (corresponding to approximately EUR 0.56) per A and B share. In addition to this year-end dividend, an interim dividend of DKK 2.00 (EUR ~0.27) was disbursed on September 3, 2024.
  • Approval of the Remuneration Report for 2024 (advisory vote)
  • Approval of the remuneration of members of the Board of Directors for 2025
  • Re-election of Cornelis (Cees) de Jong as Chair of the Board of Directors
  • Re-election of Heine Dalsgaard as a member of the Board of Directors and election as new Vice Chair
  • Re-election of Lise Kaae, Kasim Kutay, Kevin Lane, Morten Otto Alexander Sommer, and Kim Stratton as members of the Board of Directors
  • Election of Monila Kothari as a new member of the Board of Directors
  • Re-election of EY Godkendt Revisionspartnerselskab as the company’s auditors in respect of statutory financial and sustainability reporting
  • Approval to renew the authorizations to the Board of Directors to implement capital increases
  • Approval to renew the authorization to the Board of Directors to acquire treasury shares
  • Approval of the authorization to the Board of Directors to distribute extraordinary dividends


Composition of the Board of Directors and its committees
After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees.

Wer­bung

The Board of Directors, including its committees, is now composed as follows:

  • Cees (Cornelis) de Jong (Chair of the Board, chair of the Nomination and Remuneration Committee and member of the Audit Committee)
  • Heine Dalsgaard (Vice Chair of the Board and member of the Audit Committee)
  • Robert Nøddeskov Jensen (employee representative)
  • Lise Kaae (chair of the Audit Committee)
  • Monila Kothari (member of the Innovation Committee)
  • Kasim Kutay (member of the Nomination and Remuneration Committee)
  • Lars Bo Køppler (employee representative)
  • Kevin Lane (member of the Innovation Committee)
  • Preben Nielsen (employee representative and member of the Innovation Committee)
  • Frederikke Rose Spenner (employee representative)
  • Morten Otto Alexander Sommer (chair of the Innovation Committee)
  • Kim Stratton (member of the Nomination and Remuneration Committee)

For further information on the members of the Board of Directors, please go to www.novonesis.com

Wer­bung

Attachment


Ausgewählte Hebelprodukte auf Novozymes A-S (B)

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Novozymes A-S (B)

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Novozymes A-S (B)

Wer­bung

Analysen zu Novozymes A-S (B)

DatumRatingAnalyst
17.10.2012Novozymes holdDeutsche Bank AG
03.09.2012Novozymes buyING
28.08.2012Novozymes overweightMorgan Stanley
09.08.2012Novozymes overweightMorgan Stanley
22.06.2012Novozymes overweightMorgan Stanley
DatumRatingAnalyst
03.09.2012Novozymes buyING
28.08.2012Novozymes overweightMorgan Stanley
09.08.2012Novozymes overweightMorgan Stanley
22.06.2012Novozymes overweightMorgan Stanley
17.11.2011Novozymes overweightMorgan Stanley
DatumRatingAnalyst
17.10.2012Novozymes holdDeutsche Bank AG
15.10.2010Novozymes holdVontobel Research
13.08.2010Novozymes holdVontobel Research
DatumRatingAnalyst
05.05.2005Novozymes: Sector UnderperformVontobel

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novozymes A-S (B) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen